Healthshots on MSN7d
RSV or Respiratory Syncytial Virus: Is it a serious infection or just common cold?
Coughing, sneezing, and high temperature are common signs of a cold. While these may look harmless, they can also be symptoms ...
AL DA News6d
Coming Soon: Respiratory Syncytial Virus (RSV) Vaccine
In three months, the distribution of RSV vaccines will begin in the Americas, according to a PAHO announcement.
Opinion: The RSV vaccine will help protect older adults from the respiratory virus
Getting the annual RSV shot and other important vaccines is a fantastic way to safeguard yourself and your family as winter ...
Medscape2d
Rapid Antigen-based Testing for Respiratory Syncytial Virus
Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...
WebMD27d
RSV Vaccine Shows Strong Protection for Older Adults
Oct. 18, 2024 – Older people who aren’t sure about whether to get the vaccine for respiratory syncytial virus (RSV) now have a new set of data to help them make up their minds. A large study ...
Glamour on MSN12d
RSV Symptoms: Here’s How the Virus Shows Up Differently in Babies, Adults, and Seniors
Just like adults under 60, elderly adults who get RSV tend to have mild symptoms, such as runny nose, sore throat, cough, ...
Business Wire21d
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, Show Potential to Help Protect a Broader Group of Adults at Increased Risk for RSV Disease
PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine ... s Annual Report on Form 20-F for 2023, and GSK ...
Channel NewsAsia Singapore1mon
More than just a cold: Understanding the respiratory syncytial virus
The highly contagious respiratory syncytial virus (RSV) typically causes mild illness, but it can lead to severe respiratory complications, particularly for at-risk individuals. Drawing on local ...
Yahoo Finance21d
FDA Approves Pfizer's Respiratory Syncytial Virus Vaccine Abrysvo For Adults Below 60 Years
On Tuesday, the FDA approved Pfizer Inc’s (NYSE:PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower respiratory tract ...
Yahoo Finance23d
U.S. FDA Approves Pfizer’s RSV Vaccine ABRYSVO® for Adults Aged 18 to 59 at Increased Risk for Disease
NEW YORK, October 22, 2024--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved ABRYSVO ® (Respiratory Syncytial Virus Vaccine ...
Daily Corinthian15d
State recommends respiratory virus vaccinations
As the weather gets colder, respiratory viruses become more common. Illnesses like influenza, COVID-19 and respiratory syncytial virus pose the risk of severe outcomes, such as hospitalization and ...
Medscape3d
Rapid Antigen-based Testing for Respiratory Syncytial Virus
as the presentation is indistinguishable from other respiratory tract infections, and epidemics often overlap. The microbiologic confirmation of RSV infection is based on detecting the virus in a ...